Sara Vandenwijngaert

Sara Vandenwijngaert is a professional with a background in biomedical sciences and extensive experience in both research and venture capital. Currently serving as a Junior Partner and Investment Manager at Qbic Fund, Sara is involved in investing in seed and early-stage ventures. Sara also holds board positions at Tanai Therapeutics, ABSCINT, and THERAtRAME, and previously served as an Associate Director at Medpace. With a Ph.D. in Biomedical Sciences from KU Leuven, Sara has also worked as an Instructor at Harvard Medical School and conducted postdoctoral research at Harvard Medical School and Massachusetts General Hospital.